ArticleInternational journal of cancer2025
Genetic variants linked to type 2 diabetes in CDKN1B and TCF7L2 influence survival outcomes in metastatic colorectal cancer.
Article in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- p27 Expression in Wild-Type KRAS Colon Cancer.Journal of cellular and molecular medicine · 2026Article
- Genetic variants linked to type 2 diabetes in CDKN1B and TCF7L2 influence survival outcomes in metastatic colorectal cancer.International journal of cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Evidence suggests that metastatic colorectal cancer patients with type 2 diabetes (T2D) experience a poorer prognosis in contrast to their non-diabetic counterparts. Considering the multifactorial genetic nature of colon cancer development, we examined whether gene polymorphisms associated with T2D could affect the clinical outcome of metastatic colon cancer. Using in silico analysis, we evaluated gene variants linked to both T2D and colon cancer utilizing data from The Cancer Genome Atlas (TCGA). Subsequently, we assessed the prognostic relevance of polymorphisms in CCND2, CDKN1B, CDKN2A, CDKN2B, EML4, HNF1A, ID3, IGF1, IGF1R, IGF2, INHBA, INSR, IRS1, IRS2, and TCF7L2 in a cohort of 99 consecutive metastatic non-diabetic colon cancer patients with favorable clinical conditions. Primary colon cancer DNA was sequenced using the TruSight Oncology 500 kit, followed by sequencing on an Illumina NovaSeq 6000 platform. Notably, patients carrying the CDKN1B p.V109G and TCF7L2 p.P370R polymorphisms exhibited significantly shorter median survivals compared to wild-type counterparts, with adjusted hazard ratios (covariates: age, gender, metastatic extent, RAS/BRAF mutations, and response to therapy) of 2.28 (95% CI: 1.18-4.41) and 4.45 (95% CI: 1.26-15.70), respectively. Our findings provide scientific evidence of T2D genetic polymorphisms' involvement in determining the aggressiveness of metastatic colon cancer, identifying CDKN1B p.V109G and TCF7L2 p.P370R as novel unfavorable prognostic markers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.